Seres Therapeutics (MCRB) Non-Current Debt (2014 - 2024)

Seres Therapeutics has disclosed Non-Current Debt across 11 years of filings, most recently posting $102.5 million for Q2 2024.

• In Q2 2024, Non-Current Debt rose 1.74% year-over-year to $102.5 million; the TTM figure through Jun 2024 stood at $102.5 million (up 1.74% YoY), while the FY2023 annual figure was $101.5 million, up 100.72% from the prior year.
• Non-Current Debt came in at $102.5 million for Q2 2024 at Seres Therapeutics, roughly flat from $102.0 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $102.5 million in Q2 2024 to a low of $16.1 million in Q3 2021.
• Average Non-Current Debt over 5 years is $52.4 million, with a median of $50.5 million recorded in 2022.
• Year-over-year, Non-Current Debt plunged 35.47% in 2021 and jumped 215.55% in 2022.
• Over 5 years, Non-Current Debt stood at $24.6 million in 2020, then climbed by 0.02% to $24.6 million in 2021, then jumped by 105.3% to $50.6 million in 2022, then jumped by 100.72% to $101.5 million in 2023, then increased by 0.94% to $102.5 million in 2024.
• Per Business Quant data, the three most recent Non-Current Debt figures were $102.5 million in Q2 2024, $102.0 million in Q1 2024, and $101.5 million in Q4 2023.